Your Health, We Care
On March 19, 2024, Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental New Drug Application (sNDA) for ponatinib (Iclusig, generic name: ponatinib) for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Takeda Pharmaceutical’s ponatinib (Iclusig, generic name: ponatinib) for the treatment of adult patients with chronic-phase chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapies.
On December 14, 2012, the U.S. Food and Drug Administration (FDA) approved ponatinib (Iclusig) for the treatment of two rare types of leukemia.
Ponatinib is an oral targeted drug specifically indicated for the treatment of chronic myeloid leuke···【more】
Recommended：542026-20-01
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the U.S. Food and Drug Admini···【more】
Recommended：522026-20-01
Ponatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), was developed by Ariad Pharma···【more】
Recommended：472026-20-01
On March 19, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved the supp···【more】
Recommended：772026-20-01
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the Phase 3 PhALLCON trial—a ···【more】
Recommended：702026-20-01
Ponatinib is an oral targeted drug specifically indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemi···【more】
Article source：Lucius LaosRelease date：2026-01-20Recommended：54
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for pon···【more】
Article source：Lucius LaosRelease date：2026-01-20Recommended：52
Ponatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), was developed by Ariad Pharmaceuticals. The drug has obtained approval from the U.S. Food and Drug Administra···【more】
Article source：Lucius LaosRelease date：2026-01-20Recommended：47
On March 19, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ponatinib, for use in combination with ···【more】
Article source：Lucius LaosRelease date：2026-01-20Recommended：77
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the Phase 3 PhALLCON trial—a randomized, international, open-label, multicenter study—is evaluating the effic···【more】
Article source：Lucius LaosRelease date：2026-01-20Recommended：70
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
